It was described earlier that CUDC-907 could restore cisplatin sensitivity in cancer cells by decreasing ABCC2 expression, resulting in the accumulation of platinum drugs in the cells and increased cell cycle arrest [42]. Here, ABCC2 is linked to cancer.